Sean Wharton

New Capabilities

Presented the trial results at ObesityWeek 2026

A lower dose of Novo Nordisk's experimental obesity drug CagriSema produced about 21% average weight loss over 68 weeks, the company reported. That is close to the 22.7% the program's highest dose produced in an earlier trial, though the two studies used different designs and are not directly comparable.

Updated 1 hour ago